Claims for Patent: 8,017,615

Summary for Patent: 8,017,615

Title:	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract:	The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s):	Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	11/790,605
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,017,615
Patent Claims:	1. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating Anhydrous Aripiprazole Crystals B with one or more pharmaceutically acceptable carriers, obtaining granules of Anhydrous Aripiprazole Crystals B, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less. 2. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating Anhydrous Aripiprazole Crystals B with one or more pharmaceutically acceptable carriers, obtaining granules of Anhydrous Aripiprazole Crystals B, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less. 3. A pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and one or more pharmaceutically acceptable carriers, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; wherein said Crystals have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 4. A pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals B having low hygroscopicity and one or more pharmaceutically acceptable carriers, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; wherein said Crystals have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 5. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating conventional Anhydrous Aripiprazole Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Anhydrous Aripiprazole Crystals, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain a pharmaceutical solid oral preparation. 6. A pharmaceutical solid oral preparation prepared by wet granulating conventional Anhydrous Aripiprazole Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Anhydrous Aripiprazole Crystals, drying the obtained granules at 70 to 100.degree. C., sizing the obtained granules, and then drying the sized granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain said pharmaceutical solid oral preparation wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 7. The pharmaceutical solid oral preparation prepared by the process of claim 5, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 8. A process for preparing a pharmaceutical solid oral preparation comprising wet granulating conventional Aripiprazole Hydrate Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Aripiprazole Hydrate Crystals, drying the obtained granules at 70 to 100.degree. C., shaping the obtained granules, and then drying the shaped granules at 70 to 100.degree. C. for 1 to 6 hours again to obtain the pharmaceutical solid oral preparation. 9. A pharmaceutical solid oral preparation prepared by wet granulating conventional Aripiprazole Hydrate Crystals and one or more pharmaceutically acceptable carriers, obtaining granules of conventional Aripiprazole Hydrate Crystals, drying the obtained granules at 70 to 100.degree. C., sizing the obtained granules, and then drying the sized granules at 70 to 100.degree. C. for 1 to 6 hours again, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 10. The pharmaceutical solid oral preparation prepared by the process of claim 8, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes. 11. A process for preparing a pharmaceutical solid oral preparation of Anhydrous Aripiprazole Crystals B and one or more pharmaceutically acceptable carriers comprising heating Aripiprazole Hydrate A at 90 to 125.degree. C. for about 3 to 50 hours wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.40% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less; and said Aripiprazole Hydrate A has a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree. and 24.8.degree.; particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum; a thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min) endothermic curve characterized by the appearance of a peak at about 71.degree. C. and an endothermic peak around 60.degree. C. to 120.degree. C.; and a mean particle size of 50 .mu.m or less. 12. A process for preparing a pharmaceutical solid oral preparation of Anhydrous Aripiprazole Crystals B and one or more pharmaceutically acceptable carriers comprising heating Aripiprazole Hydrate A at 90 to 125.degree. C. for about 3 to 50 hours wherein said Anhydrous Aripiprazole Crystals B have low hygroscopicity, wherein said low hygroscopicity is a moisture content of 0.10% or less after placing said Crystals for 24 hours in a desiccator maintained at a temperature of 60.degree. C. and a humidity level of 100%; have a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=11.0.degree., 16.6.degree., 19.3.degree., 20.3.degree., and 22.1.degree.; have particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960, and 779 cm.sup.-1 on the IR (KBr) spectrum; exhibit an endothermic peak near about 141.5.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); exhibit an endothermic peak near about 140.7.degree. C. in differential scanning calorimetry (heating rate 5.degree. C./min); and have a mean particle size of 50 .mu.m or less; and wherein said Aripiprazole Hydrate A has a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree. and 24.8.degree.; particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum; a thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min) endothermic curve characterized by the appearance of a peak at about 71.degree. C. and an endothermic peak around 60.degree. C. to 120.degree. C.; and a mean particle size of 50 .mu.m or less. 13. The process according to claim 1, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 14. The process according to claim 2, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 15. The pharmaceutical solid oral preparation according to claim 3, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 16. The pharmaceutical solid oral preparation according to claim 4, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 17. The process according to claim 11, wherein the mean particle size is measured using a laser diffraction particle size analyzer. 18. The process according to claim 12, wherein the mean particle size is measured using a laser diffraction particle size analyzer.